We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Waters Launches BD FACSDiscover A7 for Advanced Flow Cytometry
Read MoreHide Full Article
Key Takeaways
Waters launched the FACSDiscover A7 globally, expanding access to advanced spectral flow cytometry.
WAT's analyzer supports 50 cell characteristics with up to five lasers and 78 fluorescence detectors.
Waters adds automated calibration, hands-free loading and guided workflows to improve reproducibility.
Waters Corporation (WAT - Free Report) recently announced the global commercial launch of the BD FACSDiscover A7 Cell Analyzer, expanding access to advanced spectral flow cytometry for academic, pharmaceutical and contract research organization (CRO) laboratories. The new analyzer combines high spectral resolution and sensitivity with automated standardization and user-friendly features, enabling researchers to conduct routine experiments while improving data consistency and reproducibility.
Per management, the FACSDiscover A7 Cell Analyzer combines advanced spectral capabilities with robust standardization and an attractive price-to-performance proposition, making spectral flow cytometry more accessible to researchers across applications such as biomarker discovery and drug development. The analyzer builds on the company’s recent advancements in 50-color flow cytometry, helping laboratories address the growing need for reproducible results through an integrated ecosystem of instruments, reagents and informatics.
Likely Trend of WAT Stock Following the News
WAT stock has gained 4.8% since the announcement on Monday. Year to date, the stock rose 13.1%, outperforming the industry’s 6.9% decline and the S&P 500’s 11.3% gain.
The launch is expected to strengthen Waters’ position in the growing flow cytometry market by expanding its portfolio of advanced analytical instruments. The FACSDiscover A7 could support demand among research laboratories seeking higher-throughput and reproducible workflows, while its combination of spectral capabilities, automation and ease of use may broaden adoption among new users. The product also complements Waters’ broader focus on life sciences and analytical technologies.
WAT currently has a market capitalization of $41.13 billion.
Image Source: Zacks Investment Research
More on the BD FACSDiscover A7 Cell Analyzer
The BD FACSDiscover A7 incorporates BD SpectralFX Technology, which combines full-spectrum optics, optimized hardware and system-aware unmixing algorithms to improve spectral resolution and sensitivity. The technology supports up to five lasers and 78 fluorescence detectors, allowing researchers to analyze more than 50 characteristics of individual cells while maintaining consistent data quality.
The analyzer also features FACSTruQ Technology, which provides automated instrument calibration, setup and quality control. Combined with Detector Setting Independent (DSI) scaling, the platform is designed to improve reproducibility across instruments, users and sites. Waters stated that the system achieves a coefficient of variation of less than 10% across a palette of more than 50 dyes.
Automation is another major component of the FACSDiscover A7. Its integrated autoloader enables hands-free sample acquisition while minimizing manual intervention and supporting continuous operation. The system also incorporates BD FACSChorus Software, which provides guided workflows to simplify setup and reduce learning curves for users.
With event rates of up to 35,000 events per second, automated workflows and features supporting 21 CFR Part 11 compliance, the FACSDiscover A7 is designed to help laboratories improve efficiency while generating standardized, high-quality flow cytometry data. The analyzer is now commercially available globally through local representatives.
Industry Prospects Favoring the Market
Going by the data provided by Precedence Research, the global flow cytometry market is estimated to reach $6.59 billion in 2026 and is projected to witness a CAGR of 7.8% through 2035.
Factors such as the rising prevalence of chronic diseases, growing demand for precision medicine, increasing adoption of spectral flow cytometry and high-parameter analyzers, expanding applications in immunology and oncology research, greater use of flow cytometry in stem cell therapies and drug discovery and the integration of artificial intelligence and machine learning for automated data analysis are supporting market growth.
Other News
In July, Waters launched the Xevo TQ Absolute XR IVD Mass Spectrometer, expanding its MassTrak IVD System portfolio. Designed for routine clinical testing, the system offers up to five times greater sensitivity, enabling accurate trace-level quantification from smaller samples. Its StepWave XR Ion Guide enhances robustness and ion ratio consistency, while integration with the ACQUITY UPLC I-Class PLUS System supports fast, reliable analysis of complex clinical samples.
Veracyte reported a second-quarter 2026 adjusted earnings per share (EPS) of 54 cents, which surpassed the Zacks Consensus Estimate by 25.6%. Revenues of $150.3 million beat the Zacks Consensus Estimate by 4.1%.
VCYT has an estimated earnings growth rate of 8.4% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 41.8%.
Globus Medical reported a second-quarter 2026 adjusted EPS of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
Inspire Medical reported second-quarter 2026 adjusted EPS of 14 cents, which beat the Zacks Consensus Estimate by 163.6%. Revenues of $200.6 million surpassed the Zacks Consensus Estimate by 2.9%.
INSP has an estimated long-term earnings growth rate of 10.6%. INSP’s earnings surpassed estimates in the trailing four quarters, the average surprise being 195.9%.
View the Zacks #1 Rank List
Image: Bigstock
Waters Launches BD FACSDiscover A7 for Advanced Flow Cytometry
Key Takeaways
Waters Corporation (WAT - Free Report) recently announced the global commercial launch of the BD FACSDiscover A7 Cell Analyzer, expanding access to advanced spectral flow cytometry for academic, pharmaceutical and contract research organization (CRO) laboratories. The new analyzer combines high spectral resolution and sensitivity with automated standardization and user-friendly features, enabling researchers to conduct routine experiments while improving data consistency and reproducibility.
Per management, the FACSDiscover A7 Cell Analyzer combines advanced spectral capabilities with robust standardization and an attractive price-to-performance proposition, making spectral flow cytometry more accessible to researchers across applications such as biomarker discovery and drug development. The analyzer builds on the company’s recent advancements in 50-color flow cytometry, helping laboratories address the growing need for reproducible results through an integrated ecosystem of instruments, reagents and informatics.
Likely Trend of WAT Stock Following the News
WAT stock has gained 4.8% since the announcement on Monday. Year to date, the stock rose 13.1%, outperforming the industry’s 6.9% decline and the S&P 500’s 11.3% gain.
The launch is expected to strengthen Waters’ position in the growing flow cytometry market by expanding its portfolio of advanced analytical instruments. The FACSDiscover A7 could support demand among research laboratories seeking higher-throughput and reproducible workflows, while its combination of spectral capabilities, automation and ease of use may broaden adoption among new users. The product also complements Waters’ broader focus on life sciences and analytical technologies.
WAT currently has a market capitalization of $41.13 billion.
Image Source: Zacks Investment Research
More on the BD FACSDiscover A7 Cell Analyzer
The BD FACSDiscover A7 incorporates BD SpectralFX Technology, which combines full-spectrum optics, optimized hardware and system-aware unmixing algorithms to improve spectral resolution and sensitivity. The technology supports up to five lasers and 78 fluorescence detectors, allowing researchers to analyze more than 50 characteristics of individual cells while maintaining consistent data quality.
The analyzer also features FACSTruQ Technology, which provides automated instrument calibration, setup and quality control. Combined with Detector Setting Independent (DSI) scaling, the platform is designed to improve reproducibility across instruments, users and sites. Waters stated that the system achieves a coefficient of variation of less than 10% across a palette of more than 50 dyes.
Automation is another major component of the FACSDiscover A7. Its integrated autoloader enables hands-free sample acquisition while minimizing manual intervention and supporting continuous operation. The system also incorporates BD FACSChorus Software, which provides guided workflows to simplify setup and reduce learning curves for users.
With event rates of up to 35,000 events per second, automated workflows and features supporting 21 CFR Part 11 compliance, the FACSDiscover A7 is designed to help laboratories improve efficiency while generating standardized, high-quality flow cytometry data. The analyzer is now commercially available globally through local representatives.
Industry Prospects Favoring the Market
Going by the data provided by Precedence Research, the global flow cytometry market is estimated to reach $6.59 billion in 2026 and is projected to witness a CAGR of 7.8% through 2035.
Factors such as the rising prevalence of chronic diseases, growing demand for precision medicine, increasing adoption of spectral flow cytometry and high-parameter analyzers, expanding applications in immunology and oncology research, greater use of flow cytometry in stem cell therapies and drug discovery and the integration of artificial intelligence and machine learning for automated data analysis are supporting market growth.
Other News
In July, Waters launched the Xevo TQ Absolute XR IVD Mass Spectrometer, expanding its MassTrak IVD System portfolio. Designed for routine clinical testing, the system offers up to five times greater sensitivity, enabling accurate trace-level quantification from smaller samples. Its StepWave XR Ion Guide enhances robustness and ion ratio consistency, while integration with the ACQUITY UPLC I-Class PLUS System supports fast, reliable analysis of complex clinical samples.
Waters Corporation Price
Waters Corporation price | Waters Corporation Quote
WAT’s Zacks Rank & Key Picks
Waters currently carries a Zacks Rank #3 (Hold).
Some top-ranked stocks from the broader medical space are Veracyte (VCYT - Free Report) , Globus Medical (GMED - Free Report) and Inspire Medical Systems (INSP - Free Report) , each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Veracyte reported a second-quarter 2026 adjusted earnings per share (EPS) of 54 cents, which surpassed the Zacks Consensus Estimate by 25.6%. Revenues of $150.3 million beat the Zacks Consensus Estimate by 4.1%.
VCYT has an estimated earnings growth rate of 8.4% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 41.8%.
Globus Medical reported a second-quarter 2026 adjusted EPS of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
Inspire Medical reported second-quarter 2026 adjusted EPS of 14 cents, which beat the Zacks Consensus Estimate by 163.6%. Revenues of $200.6 million surpassed the Zacks Consensus Estimate by 2.9%.
INSP has an estimated long-term earnings growth rate of 10.6%. INSP’s earnings surpassed estimates in the trailing four quarters, the average surprise being 195.9%.